Related Experiment Video
Updated: Jul 20, 2026
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
[Epidermal growth factor receptor inhibitors side effects].
Guillermo Guhl1, Ana González-de Arriba, Esteban Daudén
1Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, España. guhl@aedv.es
Actas Dermo-Sifiliograficas
|September 8, 2006
Summary
Epidermal growth factor receptor (EGFR) inhibitors treat cancers like lung and colorectal cancer. This review details common skin side effects such as rashes and dry skin, and management strategies.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) inhibitors represent a novel class of targeted cancer therapies.
- Approved EGFR inhibitors include gefitinib, erlotinib, and cetuximab for non-small-cell lung cancer and colorectal cancer.
- These targeted therapies are associated with frequent and characteristic cutaneous adverse events.
Purpose of the Study:
- To review the common dermatological side effects associated with EGFR inhibitor therapy.
- To provide guidance on the management of these frequently occurring skin toxicities.
Main Methods:
- Literature review of clinical trials and published data on EGFR inhibitor-induced skin toxicities.
- Synthesis of information regarding the incidence, clinical presentation, and management strategies for acneiform rash, paronychia, and xerosis.
Main Results:
- Acneiform rash, paronychia, and generalized xerosis are the most prevalent cutaneous side effects.
- These side effects can significantly impact patient quality of life and treatment adherence.
- Established management protocols exist for mitigating and treating these dermatological toxicities.
Conclusions:
- Cutaneous side effects are a significant clinical challenge in patients treated with EGFR inhibitors.
- Effective management of skin toxicities is crucial for maintaining treatment efficacy and patient well-being.
- Further research may focus on predictive biomarkers and novel therapeutic approaches for EGFR inhibitor-associated dermatopathies.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Transducer Mechanism: G Protein–Coupled Receptors
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
GPCRs are also called heptahelical, 7TM, or...